Thailand · Delayed Price · Currency is THB Bumrungrad Hospital PCL Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw modest revenue growth, strong EBITDA margin, and robust Middle East contributions, while Thai patient revenue declined amid economic headwinds. Outlook for Q2 is slightly improved, with continued focus on cost control, new clinic openings, and expansion of advanced medical services.
-
Q1 2026 delivered modest revenue growth, record EBITDA margin, and strong non-Thai patient performance, especially from the Middle East. New projects in Phuket and Bangladesh are progressing, while Centers of Excellence and specialty services saw robust growth.
Fiscal Year 2025
-
Q3 2025 delivered record margins and profit growth, driven by strong international patient demand, especially from the Middle East and South Asia, offsetting declines from China and Cambodia. Cash and investments rose, and the hospital remains on track with major expansion projects.
-
Q2 2025 revenue declined 3.6% year-over-year to THB 6,104 million, but EBITDA margin hit a record 41.6% due to strong cost control. Middle East patient volumes rebounded sequentially, while insurance revenue grew 12% YTD. Outlook for 2H 2025 is positive, with Q3 revenue guided up 3%-5%.
-
Q1 2025 revenue declined 5.6% year-over-year, mainly due to a 30% drop in Middle East revenue from Ramadan's early timing, while Thai patient revenue grew 1.2%. EBITDA and net profit both fell 12.6%, but cash and investments rose to THB 16 billion.
Fiscal Year 2024
-
Record-high net profit and margins in 2024, with 11% EPS growth and strong cash flow, offsetting Middle East revenue declines through diversified international and Thai/expat growth. VitalLife and insurance segments delivered robust results, and a record dividend is proposed.
-
Q3 2024 saw a 4.9% revenue decline and flat net profit, but margins remained strong due to cost control. Middle East patient revenue dropped sharply, while China and U.S. segments grew. CapEx plans and new projects, including the Phuket hospital, remain on track.
-
Q2 and 1H 2024 saw record-high margins and strong profit growth, driven by international diversification and cost management. Revenue from Qatar and China offset declines in Kuwait, while insurance and VitalLife segments posted robust gains.